aluates Reports

$ 0.0

Automative

Age-relatedMacularDegeneration (ARMD) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Published Date: November 2024

Report Code: QYRE-Auto-29H5772

Global Age relatedMacularDegeneration ARMD Drugs Market Insights and Forecast to 2028

BUY CHAPTERS

Age-relatedMacularDegeneration (ARMD) Drugs - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Code: QYRE-Auto-29H5772

Report

November 2024

Pages:102

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Regeneron Pharmaceuticals

Bayer

Santen

Kanghong Pharmaceuticals

Novartis

Eli Lilly and Company

Tracon Pharmaceuticals

Pfizer Inc

GSK

BIOCAD

Age-relatedMacularDegeneration (ARMD) Drugs - Market Size

The global market for Age-relatedMacularDegeneration (ARMD) Drugs was estimated to be worth US$ 7725.7 million in 2023 and is forecast to a readjusted size of US$ 9609.5 million by 2030 with a CAGR of 3.1% during the forecast period 2024-2030

Age-relatedMacularDegeneration (ARMD) Drugs - Market

Age-related macular degeneration (AMD) is a disease that blurs the sharp, central vision you need for “straight-ahead” activities such as reading, sewing, and driving. AMD affects the macula, the part of the eye that allows you to see fine detail.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Age-relatedMacularDegeneration (ARMD) Drugs, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Age-relatedMacularDegeneration (ARMD) Drugs by region & country, by Type, and by Application.

The Age-relatedMacularDegeneration (ARMD) Drugs market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Age-relatedMacularDegeneration (ARMD) Drugs.

Market Segmentation

Scope of Age-relatedMacularDegeneration (ARMD) Drugs - Market Report

Report Metric	Details
Report Name	Age-relatedMacularDegeneration (ARMD) Drugs - Market
Forecasted market size in 2030	US$ 9609.5 million
CAGR	3.1%
Forecasted years	2024 - 2030
Segment by Type:	Anti VEGF Drugs Photosensitive Drugs Others
Segment by Application	Exudative ARMD Atrophy ARMD
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Roche, Regeneron Pharmaceuticals, Bayer, Santen Oy, Kanghong Pharmaceuticals, Novartis, Eli Lilly and Company, TRACON Pharmaceuticals, Pfizer, GSK, BIOCAD
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Age-relatedMacularDegeneration (ARMD) Drugs manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Age-relatedMacularDegeneration (ARMD) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Age-relatedMacularDegeneration (ARMD) Drugs in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

FAQ for this report

What is the Age-relatedMacularDegeneration (ARMD) Drugs - Market size in 2030?

Ans: The Age-relatedMacularDegeneration (ARMD) Drugs - Market size in 2030 will be US$ 9609.5 million.

Who are the main players in the Age-relatedMacularDegeneration (ARMD) Drugs - Market report?

Ans: The main players in the Age-relatedMacularDegeneration (ARMD) Drugs - Market are Roche, Regeneron Pharmaceuticals, Bayer, Santen Oy, Kanghong Pharmaceuticals, Novartis, Eli Lilly and Company, TRACON Pharmaceuticals, Pfizer, GSK, BIOCAD

What are the Application segmentation covered in the Age-relatedMacularDegeneration (ARMD) Drugs - Market report?

Ans: The Applications covered in the Age-relatedMacularDegeneration (ARMD) Drugs - Market report are Exudative ARMD, Atrophy ARMD

What are the Type segmentation covered in the Age-relatedMacularDegeneration (ARMD) Drugs - Market report?

Ans: The Types covered in the Age-relatedMacularDegeneration (ARMD) Drugs - Market report are Anti VEGF Drugs, Photosensitive Drugs, Others

Recommended Reports

Eye Disease Drugs

Neurodegenerative Drugs

Ophthalmic Devices

1 Market Overview

1.1 Age-relatedMacularDegeneration (ARMD) Drugs Product Introduction

1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Market Size Forecast

1.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Trends & Drivers

1.3.1 Age-relatedMacularDegeneration (ARMD) Drugs Industry Trends

1.3.2 Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers & Opportunity

1.3.3 Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges

1.3.4 Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Competitive Analysis by Company

2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Players Revenue Ranking (2023)

2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Company (2019-2024)

2.3 Key Companies Age-relatedMacularDegeneration (ARMD) Drugs Manufacturing Base Distribution and Headquarters

2.4 Key Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Offered

2.5 Key Companies Time to Begin Mass Production of Age-relatedMacularDegeneration (ARMD) Drugs

2.6 Age-relatedMacularDegeneration (ARMD) Drugs Market Competitive Analysis

2.6.1 Age-relatedMacularDegeneration (ARMD) Drugs Market Concentration Rate (2019-2024)

2.6.2 Global 5 and 10 Largest Companies by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2023

2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2023)

2.7 Mergers & Acquisitions, Expansion

3 Segmentation by Type

3.1 Introduction by Type

3.1.1 Anti VEGF Drugs

3.1.2 Photosensitive Drugs

3.1.3 Others

3.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type

3.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (2019 VS 2023 VS 2030)

3.2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, by Type (2019-2030)

3.2.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, by Type (%) (2019-2030)

4 Segmentation by Application

4.1 Introduction by Application

4.1.1 Exudative ARMD

4.1.2 Atrophy ARMD

4.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application

4.2.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (2019 VS 2023 VS 2030)

4.2.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, by Application (2019-2030)

4.2.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, by Application (%) (2019-2030)

5 Segmentation by Region

5.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region

5.1.1 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region: 2019 VS 2023 VS 2030

5.1.2 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region (2019-2024)

5.1.3 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region (2025-2030)

5.1.4 Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region (%), (2019-2030)

5.2 North America

5.2.1 North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

5.2.2 North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

5.3 Europe

5.3.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

5.3.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

5.4 Asia Pacific

5.4.1 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

5.4.2 Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

5.5 South America

5.5.1 South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

5.5.2 South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

5.6 Middle East & Africa

5.6.1 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

5.6.2 Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

6 Segmentation by Key Countries/Regions

6.1 Key Countries/Regions Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Growth Trends, 2019 VS 2023 VS 2030

6.2 Key Countries/Regions Age-relatedMacularDegeneration (ARMD) Drugs Sales Value

6.3 United States

6.3.1 United States Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

6.3.2 United States Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

6.3.3 United States Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application, 2023 VS 2030

6.4 Europe

6.4.1 Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

6.4.2 Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

6.4.3 Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application, 2023 VS 2030

6.5 China

6.5.1 China Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

6.5.2 China Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

6.5.3 China Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application, 2023 VS 2030

6.6 Japan

6.6.1 Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

6.6.2 Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

6.6.3 Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application, 2023 VS 2030

6.7 South Korea

6.7.1 South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

6.7.2 South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

6.7.3 South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application, 2023 VS 2030

6.8 Southeast Asia

6.8.1 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

6.8.2 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

6.8.3 Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application, 2023 VS 2030

6.9 India

6.9.1 India Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019-2030

6.9.2 India Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

6.9.3 India Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application, 2023 VS 2030

7 Company Profiles

7.1 Roche

7.1.1 Roche Profile

7.1.2 Roche Main Business

7.1.3 Roche Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.1.4 Roche Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.1.5 Roche Recent Developments

7.2 Regeneron Pharmaceuticals

7.2.1 Regeneron Pharmaceuticals Profile

7.2.2 Regeneron Pharmaceuticals Main Business

7.2.3 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.2.4 Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.2.5 Regeneron Pharmaceuticals Recent Developments

7.3 Bayer

7.3.1 Bayer Profile

7.3.2 Bayer Main Business

7.3.3 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.3.4 Bayer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.3.5 Santen Oy Recent Developments

7.4 Santen Oy

7.4.1 Santen Oy Profile

7.4.2 Santen Oy Main Business

7.4.3 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.4.4 Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.4.5 Santen Oy Recent Developments

7.5 Kanghong Pharmaceuticals

7.5.1 Kanghong Pharmaceuticals Profile

7.5.2 Kanghong Pharmaceuticals Main Business

7.5.3 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.5.4 Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.5.5 Kanghong Pharmaceuticals Recent Developments

7.6 Novartis

7.6.1 Novartis Profile

7.6.2 Novartis Main Business

7.6.3 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.6.4 Novartis Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.6.5 Novartis Recent Developments

7.7 Eli Lilly and Company

7.7.1 Eli Lilly and Company Profile

7.7.2 Eli Lilly and Company Main Business

7.7.3 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.7.4 Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.7.5 Eli Lilly and Company Recent Developments

7.8 TRACON Pharmaceuticals

7.8.1 TRACON Pharmaceuticals Profile

7.8.2 TRACON Pharmaceuticals Main Business

7.8.3 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.8.4 TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.8.5 TRACON Pharmaceuticals Recent Developments

7.9 Pfizer

7.9.1 Pfizer Profile

7.9.2 Pfizer Main Business

7.9.3 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.9.4 Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.9.5 Pfizer Recent Developments

7.10 GSK

7.10.1 GSK Profile

7.10.2 GSK Main Business

7.10.3 GSK Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.10.4 GSK Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.10.5 GSK Recent Developments

7.11 BIOCAD

7.11.1 BIOCAD Profile

7.11.2 BIOCAD Main Business

7.11.3 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

7.11.4 BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Revenue (US$ Million) & (2019-2024)

7.11.5 BIOCAD Recent Developments

8 Industry Chain Analysis

8.1 Age-relatedMacularDegeneration (ARMD) Drugs Industrial Chain

8.2 Age-relatedMacularDegeneration (ARMD) Drugs Upstream Analysis

8.2.1 Key Raw Materials

8.2.2 Raw Materials Key Suppliers

8.2.3 Manufacturing Cost Structure

8.3 Midstream Analysis

8.4 Downstream Analysis (Customers Analysis)

8.5 Sales Model and Sales Channels

8.5.1 Age-relatedMacularDegeneration (ARMD) Drugs Sales Model

8.5.2 Sales Channel

8.5.3 Age-relatedMacularDegeneration (ARMD) Drugs Distributors

9 Research Findings and Conclusion

10 Appendix

10.1 Research Methodology

10.1.1 Methodology/Research Approach

10.1.2 Data Source

10.2 Author Details

10.3 Disclaimer

FEATURED COMPANIES

Roche

Regeneron Pharmaceuticals

Bayer

Santen

Kanghong Pharmaceuticals

Novartis

Eli Lilly and Company

Tracon Pharmaceuticals

Pfizer Inc

GSK

BIOCAD

List of Tables

Table 1. Age-relatedMacularDegeneration (ARMD) Drugs Market Trends

Table 2. Age-relatedMacularDegeneration (ARMD) Drugs Market Drivers & Opportunity

Table 3. Age-relatedMacularDegeneration (ARMD) Drugs Market Challenges

Table 4. Age-relatedMacularDegeneration (ARMD) Drugs Market Restraints

Table 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue by Company (2019-2024) & (US$ Million)

Table 6. Global Age-relatedMacularDegeneration (ARMD) Drugs Revenue Market Share by Company (2019-2024)

Table 7. Key Companies Age-relatedMacularDegeneration (ARMD) Drugs Manufacturing Base Distribution and Headquarters

Table 8. Key Companies Age-relatedMacularDegeneration (ARMD) Drugs Product Type

Table 9. Key Companies Time to Begin Mass Production of Age-relatedMacularDegeneration (ARMD) Drugs

Table 10. Global Age-relatedMacularDegeneration (ARMD) Drugs Companies Market Concentration Ratio (CR5 and HHI)

Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Age-relatedMacularDegeneration (ARMD) Drugs as of 2023)

Table 12. Mergers & Acquisitions, Expansion Plans

Table 13. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)

Table 14. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (2019-2024) & (US$ Million)

Table 15. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (2025-2030) & (US$ Million)

Table 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share in Value by Type (2019-2024) & (%)

Table 17. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share in Value by Type (2025-2030) & (%)

Table 18. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)

Table 19. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (2019-2024) & (US$ Million)

Table 20. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (2025-2030) & (US$ Million)

Table 21. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share in Value by Application (2019-2024) & (%)

Table 22. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Market Share in Value by Application (2025-2030) & (%)

Table 23. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 24. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region (2019-2024) & (US$ Million)

Table 25. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region (2025-2030) & (US$ Million)

Table 26. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region (2019-2024) & (%)

Table 27. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Region (2025-2030) & (%)

Table 28. Key Countries/Regions Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030

Table 29. Key Countries/Regions Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2024) & (US$ Million)

Table 30. Key Countries/Regions Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2025-2030) & (US$ Million)

Table 31. Roche Basic Information List

Table 32. Roche Description and Business Overview

Table 33. Roche Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 34. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Roche (2019-2024)

Table 35. Roche Recent Developments

Table 36. Regeneron Pharmaceuticals Basic Information List

Table 37. Regeneron Pharmaceuticals Description and Business Overview

Table 38. Regeneron Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 39. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Regeneron Pharmaceuticals (2019-2024)

Table 40. Regeneron Pharmaceuticals Recent Developments

Table 41. Bayer Basic Information List

Table 42. Bayer Description and Business Overview

Table 43. Bayer Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 44. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Bayer (2019-2024)

Table 45. Bayer Recent Developments

Table 46. Santen Oy Basic Information List

Table 47. Santen Oy Description and Business Overview

Table 48. Santen Oy Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 49. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Santen Oy (2019-2024)

Table 50. Santen Oy Recent Developments

Table 51. Kanghong Pharmaceuticals Basic Information List

Table 52. Kanghong Pharmaceuticals Description and Business Overview

Table 53. Kanghong Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 54. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Kanghong Pharmaceuticals (2019-2024)

Table 55. Kanghong Pharmaceuticals Recent Developments

Table 56. Novartis Basic Information List

Table 57. Novartis Description and Business Overview

Table 58. Novartis Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 59. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Novartis (2019-2024)

Table 60. Novartis Recent Developments

Table 61. Eli Lilly and Company Basic Information List

Table 62. Eli Lilly and Company Description and Business Overview

Table 63. Eli Lilly and Company Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 64. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Eli Lilly and Company (2019-2024)

Table 65. Eli Lilly and Company Recent Developments

Table 66. TRACON Pharmaceuticals Basic Information List

Table 67. TRACON Pharmaceuticals Description and Business Overview

Table 68. TRACON Pharmaceuticals Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 69. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of TRACON Pharmaceuticals (2019-2024)

Table 70. TRACON Pharmaceuticals Recent Developments

Table 71. Pfizer Basic Information List

Table 72. Pfizer Description and Business Overview

Table 73. Pfizer Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 74. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of Pfizer (2019-2024)

Table 75. Pfizer Recent Developments

Table 76. GSK Basic Information List

Table 77. GSK Description and Business Overview

Table 78. GSK Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 79. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of GSK (2019-2024)

Table 80. GSK Recent Developments

Table 81. BIOCAD Basic Information List

Table 82. BIOCAD Description and Business Overview

Table 83. BIOCAD Age-relatedMacularDegeneration (ARMD) Drugs Products, Services and Solutions

Table 84. Revenue (US$ Million) in Age-relatedMacularDegeneration (ARMD) Drugs Business of BIOCAD (2019-2024)

Table 85. BIOCAD Recent Developments

Table 86. Key Raw Materials Lists

Table 87. Raw Materials Key Suppliers Lists

Table 88. Age-relatedMacularDegeneration (ARMD) Drugs Downstream Customers

Table 89. Age-relatedMacularDegeneration (ARMD) Drugs Distributors List

Table 90. Research Programs/Design for This Report

Table 91. Key Data Information from Secondary Sources

Table 92. Key Data Information from Primary Sources

Table 93. Business Unit and Senior & Team Lead Analysts

List of Figures

Figure 1. Age-relatedMacularDegeneration (ARMD) Drugs Product Picture

Figure 2. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (2019-2030) & (US$ Million)

Figure 4. Age-relatedMacularDegeneration (ARMD) Drugs Report Years Considered

Figure 5. Global Age-relatedMacularDegeneration (ARMD) Drugs Players Revenue Ranking (2023) & (US$ Million)

Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Age-relatedMacularDegeneration (ARMD) Drugs Revenue in 2023

Figure 7. Age-relatedMacularDegeneration (ARMD) Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 8. Anti VEGF Drugs Picture

Figure 9. Photosensitive Drugs Picture

Figure 10. Others Picture

Figure 11. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)

Figure 12. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Type, 2023 & 2030

Figure 13. Product Picture of Exudative ARMD

Figure 14. Product Picture of Atrophy ARMD

Figure 15. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)

Figure 16. Global Age-relatedMacularDegeneration (ARMD) Drugs Sales Value Market Share by Application, 2023 & 2030

Figure 17. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (2019-2030) & (US$ Million)

Figure 18. North America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

Figure 19. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (2019-2030) & (US$ Million)

Figure 20. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

Figure 21. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (2019-2030) & (US$ Million)

Figure 22. Asia Pacific Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

Figure 23. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (2019-2030) & (US$ Million)

Figure 24. South America Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

Figure 25. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (2019-2030) & (US$ Million)

Figure 26. Middle East & Africa Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Country (%), 2023 VS 2030

Figure 27. Key Countries/Regions Age-relatedMacularDegeneration (ARMD) Drugs Sales Value (%), (2019-2030)

Figure 28. United States Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 29. United States Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

Figure 30. United States Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (%), 2023 VS 2030

Figure 31. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 32. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

Figure 33. Europe Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (%), 2023 VS 2030

Figure 34. China Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 35. China Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

Figure 36. China Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (%), 2023 VS 2030

Figure 37. Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 38. Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

Figure 39. Japan Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (%), 2023 VS 2030

Figure 40. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 41. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

Figure 42. South Korea Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (%), 2023 VS 2030

Figure 43. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 44. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

Figure 45. Southeast Asia Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (%), 2023 VS 2030

Figure 46. India Age-relatedMacularDegeneration (ARMD) Drugs Sales Value, (2019-2030) & (US$ Million)

Figure 47. India Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Type (%), 2023 VS 2030

Figure 48. India Age-relatedMacularDegeneration (ARMD) Drugs Sales Value by Application (%), 2023 VS 2030

Figure 49. Age-relatedMacularDegeneration (ARMD) Drugs Industrial Chain

Figure 50. Age-relatedMacularDegeneration (ARMD) Drugs Manufacturing Cost Structure

Figure 51. Channels of Distribution (Direct Sales, and Distribution)

Figure 52. Bottom-up and Top-down Approaches for This Report

Figure 53. Data Triangulation

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$3950

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$5925

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$7900

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Macular Degeneration Treatment Market Research Report 2024

Global Macular Degeneration AMD and Other Retinal Diseases Market Research Report 2024

Global Ophthalmology for Age related Macular Degeneration Diseases Market Research Report 2024

Global Ophthalmology Disorders Drug Market Insights Forecast to 2030

Global Macular Edema and Macular Degeneration Market Research Report 2025

Geographic Atrophy Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Geographic Atrophy Drugs Market Research Report 2024

Global Geographic Atrophy Market Research Report 2025

Global Anti VEGF Drugs for the Treatment of Wet AMD Market Research Report 2024

Global Ranibizumab Injection Market Research Report 2024

Global Alzheimer s Disease Drug Market Insights Forecast to 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions